Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGV004 in Refractory/Relapsed B-cell Lymphoma
NCT04887025Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RGV-004 in B cell lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 28 days and Treatment-related Adverse Events at 2 years. Status: unknown.
02
Drugs
RGV-004
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04887025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887025.